Identification of HLA-DRB1-bound self-peptides following measles virus infection

Journal of Immunological Methods

Volumn 297, Issue 1-2, 2005, Pages 153-167

  Ovsyannikova, Inna G ^a   Johnson, Kenneth L ^b   Naylor, Stephen ^b,d   Poland, Gregory A ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Prog Translational I   (United States)

^d Beyond Genomics   (United States)

Author keywords

HLA DRB1*03; Mass spectrometry; Measles virus; Self peptides; Spectrum analysis

Indexed keywords

HLA DR ANTIGEN; MEASLES VACCINE; MEMBRANE PROTEIN;

ALLELE; AMINO ACID SEQUENCE; ANALYTIC METHOD; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGENETICS; MEASLES; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

MEASLES VIRUS;

EID: 15244359468     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2004.12.020     Document Type: Article

References (59)

1. M. Anafi, F. Kiefer, G.D. Gish, G. Mbamalu, N.N. Iscove, and T. Pawson SH2/SH3 adaptor proteins can link tyrosine kinases to a Ste20-related protein kinase, HPK1 J. Biol. Chem. 272 1997 27804
2. B.P. Chen, A. Madrigal, and P. Parham Cytotox T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule J. Exp. Med. 172 1990 779
3. R.M. Chicz, R.G. Urban, W.S. Lane, J.C. Gorga, L.J. Stern, D.A.A. Vignali, and J.L. Strominger Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size Nature 358 1992 764
4. R.M. Chicz, R.G. Urban, J.C. Gorga, D.A.A. Vignali, W.S. Lane, and J.L. Strominger Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles J. Exp. Med. 178 1993 27
5. M.E. Cramp, P. Carucci, J. Underhill, N.V. Naoumov, R. Williams, and P.T. Donaldson Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia J. Hepatol. 29 1998 207
6. P. Cresswell, and J.C. Howard Antigen recognition. Editorial overview Curr. Opin. Immunol. 9 1997 71
7. M.P. Davenport, and A.V.S. Hill Reverse immunogenetics: from HLA-disease associations to vaccine candidates Mol. Med. Today 2 1996 38
8. E. Depla Interaction of viruses with annexins: a potential therapeutic target? Curr. Opin. Investig. Drugs 1 2000 415
9. J.K. Eng, A.L. McCormack, and J.R. Yates III An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database J. Am. Soc. Mass Spectrom. 5 1994 976
10. V.H. Engelhard Structure of peptides associated with class I and class II MHC molecules Annu. Rev. Immunol. 12 1994 181
11. R.N. Germain The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules Ann. N.Y. Acad. Sci. 754 1998 114
12. J.C. Gorga, V. Horejsi, D.R. Johnson, R. Raghupathy, and J.L. Strominger Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line J. Biol. Chem. 262 1987 16087
13. D.E. Griffin Immune responses during measles virus infection Curr. Top. Microbiol. Immunol. 191 1995 117
14. C.A. Herberts, K.J. Stittelaar, H.E. van der, J. van Gaans-Van den Brink, M.C.M. Poelen, P.J.M. Roholl, L.J.W. van Alphen, C.J.M. Melief, A.P.J.M. de Jong, and C.A.C.M. van Els A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway J. Gen. Virol. 82 2001 2131
15. M.R. Hilleman, E.B. Buynak, R.E. Weibel, J. Stokes Jr., J.E. Whitman Jr., and M.B. Leagus Development and evaluation of the Moraten measles virus vaccine JAMA 206 1968 587
16. d Science 256 1992 1817
17. S. Jacobson, R.P. Sekaly, C.L. Jacobson, H.F. McFarland, and E.O. Long HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells J. Virol. 63 1989 1756
18. D. Kappes, and J.L. Strominger Human class II major histocompatibility complex genes and proteins Annu. Rev. Biochem. 57 1988 991
19. D.A. Kirschmann, K.L. Duffin, C.E. Smith, J.K. Welply, S.C. Howard, B.D. Schwartz, and S.L. Woulfe Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles J. Immunol. 155 1995 5655
20. L.A. Lampson, and R. Levy Two populations of Ia-like molecules on human B cell line J. Immunol. 125 1980 293
21. R. Leopardi, J. Ilonen, L. Mattila, and A.A. Salmi Effect of measles virus infection on MHC class II expression and antigen presentation in human monocytes Cell. Immunol. 147 1993 388
22. S. Matsushita, K. Takahashi, M. Motoki, K. Komoriya, S. Ikagawa, and Y. Nishimura Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome J. Exp. Med. 180 1994 873
23. M.B. McChesney, J.H. Kehrl, A. Valsamakis, A.S. Fauci, and M.B.A. Oldstone Measles virus infection of B lymphocytes permits cellular activation but blocks progression through the cell cycle J. Virol. 61 1987 3441
24. 2 cells is epitope and major histocompatibility complex dependent J. Virol. 69 1995 2776
25. T. Nagase, R. Kikuno, K. Ishikawa, M. Hirosawa, and O. Ohara Prediction of the coding sequences of unidentified human genes: XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro DNA Res. 7 2000 143
26. D. Naniche, G. Varior-Krishnan, F. Cervoni, T.F. Wild, B. Rossi, C. Rabourdin-Combe, and D. Gerlier Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus J. Virol. 67 1993 6025
27. H. Neitzel A routine method for the establishment of permanent growing lymphoblastoid cell lines Hum. Genet. 73 1986 320
28. C. Neumeister, R. Nanan, T.I. Cornu, C.G.K. Lüder, V. ter Meulen, H. Naim, and S. Niewiesk Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway J. Gen. Virol. 82 2001 441
29. J.G. Nuchtern, W.E. Biddison, and R.D. Klausner Class II MHC molecules can use the endogenous pathway of antigen presentation Nature 343 1990 74
30. I.G. Ovsyannikova, R.M. Jacobson, R.A. Vierkant, H. Shitaye, Y. Sohni, D.J. Schaid, V.S. Pankratz, S.J. Jacobsen, and G.A. Poland The role of class II HLA homozygosity in measles vaccine virus (MVV) antibody (Ab) nonresponse Third annual conference on vaccine research abstract# P24 2000 58
31. I.G. Ovsyannikova, K.L. Johnson, S. Naylor, and G.A. Poland Isolation and rapid identification of an abundant self-peptide from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection J. Immunol. Methods 246 2000 1
32. I.G. Ovsyannikova, Y. Sohni, R.M. Jacobson, R. Vierkant, D. Schaid, S.V. Pankratz, S.J. Jacobsen, and G.A. Poland The role of class II HLA-DRB1*03 molecules in measles vaccine virus (MVV) nonresponse Keystone symposia, Keystone, Colorado abstract# 145 2000 63
33. E.G. Pamer Antigen presentation in the immune response to infectious diseases Clin. Infect. Dis. 28 1999 714
34. M. Peakman, E.J. Stevens, T. Lohmann, P. Narendran, J. Dromey, A. Alexander, A.J. Tomlinson, M. Trucco, J.C. Gorga, and R.M. Chicz Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4 J. Clin. Invest. 104 1999 1449
35. V.B. Peters, and K.E. Sperber The effect of viruses on the ability to present antigens via the major histocompatibility complex Microbes Infect. 1 1999 335
36. G.A. Poland Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response Am. J. Hum. Genet. 62 1998 215
37. G.A. Poland Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes Vaccine 17 1999 1719
38. G.A. Poland, I.G. Ovsyannikova, R.M. Jacobson, R.A. Vierkant, S.J. Jacobsen, V.S. Pankratz, and D.J. Schaid Identification of an association between HLA class II alleles and low antibody levels after measles immunization Vaccine 20 2001 430
39. G.A. Poland, I.G. Ovsyannikova, K.L. Johnson, and S. Naylor The role of mass spectrometry in vaccine development Vaccine 19 2001 2692
40. M.E. Ressing, J.H. de Jong, R.M.P. Brandt, J.W. Drijfhout, W.E. Benckhuijsen, G.M.T. Schreuder, R. Offringa, W.M. Kast, and C.J.M. Melief Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma Eur. J. Immunol. 29 1999 1292
41. D. Rimoldi, S. Salvi, D. Reed, P. Coulie, V.C. Jongeneel, E. De Plaen, F. Brasseur, A.M. Rodriguez, T. Boon, and J.C. Cerottini cDNA and protein characterization of human MAGE-10 Int. J. Cancer 82 1999 901
42. A.Y. Rudensky, P. Preston-Hurlburt, S.-C. Hong, A. Barlow, and C.A. Janeway Jr. Sequence analysis of peptides bound to MHC class II molecules Nature 353 1991 622
43. M. Schirle, W. Keilholz, B. Weber, C. Gouttefangeas, T. Dumrese, H.D. Becker, S. Stevanovic, and H.-G. Rammensee Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach Eur. J. Immunol. 30 2000 2216
44. A. Sette, and J. Sidney HLA supertypes and supermotifs: a functional perspective on HLA polymorphism Curr. Opin. Immunol. 10 1998 478
45. A. Sette, S. Ceman, R.T. Kubo, K. Sakaguchi, E. Appella, D.F. Hunt, T.A. Davis, H. Michel, J. Shabanowitz, R. Rudersdorf, H.M. Grey, and R. DeMars Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant Science 258 1992 1801
46. M.L. Silver, H.-C. Guo, J.L. Strominger, and D.C. Wiley Atomic structure of a human MHC molecule presenting an influenza virus peptide Nature 360 1992 367
47. A.P. Snyder, A.L. McCormack, J.K. Eng, P.C. DeRoos, A.Y. Rudensky, and J.R. Yates III Micro-column liquid chromatography electrospray ionization tandem mass spectrometry A.P. Snyder Analysis of immunological samples, biochemical and biotechnological applications of electrospray ionization mass spectrometry A.C.S. Symposium Series vol. 619 1995 American Chemical Society Washington, DC 207
48. J. Stachowski, J. Kramer, G. Füst, J. Maciejewski, C.A. Baldmus, and G.G. Petrányi Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients Scand. J. Immunol. 42 1995 60
49. R.L. Stevens, S. Avraham, M.C. Gartner, G.A. Bruns, K.F. Austen, and J.H. Weis Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells J. Biol. Chem. 263 1988 7287
50. T.C. Sudhof, C.A. Slaughter, I. Leznicki, P. Barjon, and G.A. Reynolds Human 67-kDa calelectrin contains a duplication of four repeats found in 35-kDa lipocortins Proc. Natl. Acad. Sci. U. S. A. 85 1988 664
51. V. Taneja, and C.S. David HLA transgenic mice as humanized mouse models of disease and immunity J. Clin. Invest. 101 1998 921
52. E. Thorsby, E. Berle, and H. Nousiainen HLA-D region molecules restrict proliferative T cell responses to antigen Immunol. Rev. 66 1982 39
53. J.L. Tiwari, and P.I. Terasaki HLA and disease associations 1985 Springer-Verlag New York, NY
54. + cytotoxic T lymphocytes J. Clin. Invest. 97 1996 577
55. R.G. Urban, R.M. Chicz, D.A. Vignali, and J.L. Strominger The dichotomy of peptide presentation by class I and class II MHC proteins Chem. Immunol. 57 1993 197
56. b molecule Nature 348 1990 213
57. C.A.C.M. van Els, C.A. Herberts, E. van der Heeft, M.C.M. Poelen, J.A.M. van Gaans-van den Brink, A. van der Kooi, P. Hoogerhout, G.J. ten Hove, H.D. Meiring, and A.P.J.M. de Jong A single naturally processed measles virus peptide fully dominates the HLA-A*00201-associated peptide display and is mutated at its anchor position in persistent viral strains Eur. J. Immunol. 30 2000 1172
58. R. Vidal, M. Calero, T. Revesz, G. Plant, J. Ghiso, and B. Frangione Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family Gene 266 2001 95
59. J. Vingerhoets, C. Goilav, G. Vanham, L. Kestens, L. Muylle, E. Kegels, J. Van Hoof, P. Piot, and P. Gigase Non-response to a recombinant pre-S2-containing hepatitis B vaccine: association with the HLA-system Ann. Soc. Belge Med. Trop. 75 1995 125